

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
8 November 2001 (08.11.2001)

PCT

(10) International Publication Number
WO 01/83811 A1

(51) International Patent Classification⁷: **C12Q 1/00**,
G01N 33/53, C12N 9/48, A61K 38/00, C07K 14/00,
C07H 21/04

07065-0907 (US). **XU, Min** [CN/US]; 126 East Lincoln Avenue, Rahway, NJ 07065-0907 (US). **HUANG, Qian** [CN/US]; 126 East Lincoln Avenue, Rahway, NJ 07065-0907 (US). **GARDELL, Stephen** [US/US]; 126 East Lincoln Avenue, Rahway, NJ 07065-0907 (US).

(21) International Application Number: PCT/US01/13332

(22) International Filing Date: 25 April 2001 (25.04.2001)

(74) Common Representative: **MERCK & CO., INC.**; 126 East Lincoln Avenue, Rahway, NJ 07065-0907 (US).

(25) Filing Language: English

(81) Designated States (*national*): CA, JP, US.

(26) Publication Language: English

(84) Designated States (*regional*): European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR).

(30) Priority Data:
60/201,053 1 May 2000 (01.05.2000) US

Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments


(71) Applicant (*for all designated States except US*): **MERCK & CO., INC.** [US/US]; 126 East Lincoln Avenue, Rahway, NJ 07065-0907 (US).

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): **LI, Yueming** [US/US]; 126 East Lincoln Avenue, Rahway, NJ

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: GAMMA SECRETASE SUBSTRATES AND IN VITRO ASSAYS



(57) Abstract: The present invention features γ -secretase substrates and *in vitro* assays for measuring γ -secretase activity employing such substrates. The γ -secretase substrates described herein contain a hydrophilic polypeptide moiety covalently joined to the carboxyl terminus of a β -CTF domain. A " β -CTF domain" is a polypeptide that can be cleaved by γ -secretase and which approximates the C-terminal fragment (amino acids 596-695) of APP produced after cleavage of APP by a β -secretase, or is a functional derivative thereof.



WO 01/83811 A1

TITLE OF THE INVENTION

GAMMA SECRETASE SUBSTRATES AND IN VITRO ASSAYS

CROSS-REFERENCE TO RELATED APPLICATIONS

- 5 The present application claims priority to provisional application U.S. Serial No. 60/201,053, filed May 1, 2000, hereby incorporated by reference herein.

BACKGROUND OF THE INVENTION

- 10 The references cited herein are not admitted to be prior art to the claimed invention.

- 15 Amyloid precursor protein (APP) is a ubiquitous membrane-spanning (type 1) glycoprotein that undergoes a variety of proteolytic processing events. (Selkoe, 1998. Trends in Cell Biology 8, 447-453.) Sequential cleavage of APP by the β - and γ -secretases generate the N- and C-termini, respectively, of A β peptides which comprise amyloid plaques in the brain parenchyma of patients with Alzheimer's disease. APP proteolysis by α -secretase occurs within the A β peptide domain thereby precluding formation of the amyloidogenic peptides. The C-termini of the A β peptides are heterogeneous. Peptides of 40 or 42 amino acids in length (A β 40 and A β 42, respectively) are typically generated. A β 42 is more prone to aggregation than A β 40 and is the major component of amyloid plaque. (Jarrett *et al.*, 20 1993. Biochemistry 32, 4693-4697; and Kuo *et al.*, 1996. J. Biol. Chem. 271, 4077-4081.)

- 25 The scissile bond for cleavage of APP by γ -secretase appears to be situated within a transmembrane domain. It is unclear as to whether the C-termini of A β 40 and A β 42 are generated by a single protease with sloppy specificity or two distinct proteases. Recent studies suggest that γ -secretase also cleaves within the transmembrane region of Notch thereby releasing the Notch intracellular domain which controls crucial cell fate decisions during development. (De Strooper *et al.*, 1999. Nature 398, 518-522.)

30

SUMMARY OF THE INVENTION

- 35 The present invention features γ -secretase substrates and *in vitro* assays for measuring γ -secretase activity employing such substrates. The γ -secretase substrates described herein contain a hydrophilic polypeptide moiety covalently joined to the carboxyl terminus of a β -CTF domain.

A “ β -CTF domain” is a polypeptide that can be cleaved by γ -secretase and which approximates the C-terminal fragment (amino acids 596-695) of APP produced after cleavage of APP by a β -secretase, or is a functional derivative thereof. Preferably, the β -CTF domain can be cleaved by a γ -secretase to produce a fragment
5 between about 39 to about 43 amino acids in length. The preferred size ranges takes into account the generation of peptides A β 40 and A β 42 from naturally occurring APP by the sequential actions of β -secretase and γ -secretase.

The hydrophilic polypeptide moiety is preferably chosen to increase the solubility of the γ -secretase substrate in a zwitterionic detergent. Hydrophilic
10 moieties can be obtained taking into account the known charges and polarity of different amino acid R groups.

Thus, a first aspect of the present invention features a γ -secretase substrate. The γ -secretase substrate contains a hydrophilic polypeptide moiety covalently joined to the carboxyl terminus of a β -CTF domain.

15 Another aspect of the present invention describes a nucleic acid comprising a nucleotide base sequence encoding a γ -secretase substrate. Preferably, the nucleic acid is an expression vector.

Another aspect of the present invention describes a recombinant cell comprising a nucleic acid encoding a γ -secretase substrate.

20 Another aspect of the present invention describes a method for assaying γ -secretase activity comprising the use of an effective amount of a zwitterionic detergent and a γ -secretase substrate. γ -Secretase activity can be obtained from cells producing γ -secretase in a solubilized form or in a membrane-bound form. The effective amount of a zwitterionic detergent is a concentration of zwitterionic
25 detergent where γ -secretase produces detectable cleavage of the γ -secretase substrate.

The method can be performed by measuring product formation resulting from γ -secretase substrate cleavage. Measuring can be performed by qualitative or quantitative techniques.

30 Another aspect of the present invention describes a method for measuring the ability of a compound to affect γ -secretase activity comprising the steps of: (a) combining together a γ -secretase substrate, a compound, and a preparation comprising γ -secretase activity, under reaction conditions allowing for γ -secretase activity, and (b) measuring γ -secretase activity. The reaction conditions allowing for γ -secretase activity comprise an effective amount of a zwitterionic detergent.

Other features and advantages of the present invention are apparent from the additional descriptions provided herein including the different examples. The provided examples illustrate different components and methodology useful in practicing the present invention. The examples do not limit the claimed invention.

5 Based on the present disclosure the skilled artisan can identify and employ other components and methodology useful for practicing the present invention.

BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 provides a schematic representation of a fusion protein consisting sequentially of an N-terminal Met (M), APP597-695 and the Flag tag (Flag) sequence, and its processing by γ -secretase. The A β 40- and A β 42-related products (M-A β 40 and M-A β 42, respectively) are detected by electrochemiluminescence (ECL) using biotinylated 4G8 antibody and ruthenylated G2-10 or FCA3542, respectively.

10

Figures 2A-2D illustrate results of experiments characterizing detergent-solubilized γ -secretase activity. (A) Dependence of M-A β 40 formation on the substrate concentration. The data show the ECL signal after a 90 minute incubation at 37°C. (B) Time dependence of M-A β 40 formation by "solubilized γ -secretase". The ECL signals are shown. (C) pH dependence of "solubilized γ -secretase" activity scoring for generation of the M-A β 40. The ECL signals are shown. (D) Inhibition of *in vitro* γ -secretase activity by pepstatin. The impact of pepstatin on the generation of M-A β 40 (○) and M-A β 42 (●) is shown. The ECL data is expressed as % of activity observed in the absence of pepstatin. Figures 2A, 2B and 2C show the mean values from two independent experiments. Figure 2D shows the mean \pm SD (n=5).

15

20

25

DETAILED DESCRIPTION OF THE INVENTION

The present invention features γ -secretase substrates and assays for detecting γ -secretase activity employing such substrates. The γ -secretase substrate can be cleaved by γ -secretase activity.

30

Assaying for γ -secretase activity can be used, for example, to purify the enzyme, to characterize the enzyme, to screen for compounds able to modulate γ -secretase activity, and to test the ability of a particular compound to affect γ -secretase activity. Examples of compounds able to modulate γ -secretase activity include γ -secretase inhibitors. Inhibitors can be employed for different purposes, such as in the

35

treatment of Alzheimer's disease or characterization of the biological importance of γ -secretase.

γ -Secretase Substrate

5 The γ -secretase substrate is a fusion protein comprising a β -CTF domain and a hydrophilic polypeptide moiety. The β -CTF domain provides a polypeptide that can be cleaved by γ -secretase activity. The hydrophilic polypeptide moiety allows for the β -CTF domain to be cleaved by detergent-solubilized γ -secretase by promoting substrate solubility.

10 The β -CTF domain approximates the C-terminal fragment of APP after cleavage by β -secretase or is a functional derivative thereof. By approximating the β -CTF portion of APP the γ -secretase substrate takes into account the cleavage of APP by α - or β -secretase appearing to be a prerequisite for γ -secretase-mediated processing.

15 A "functional derivative thereof" has a sufficient sequence similarity to the β -CTF portion of APP such that it can be cleaved by γ -secretase. Examples of modifications to a β -CTF portion of APP to produce a functional derivative include additions, deletions, and substitutions. The effect of a particular modification can be measured using reaction conditions described herein that allow for γ -secretase
20 cleavage of a γ -secretase substrate. Preferred modifications do not cause a substantial decrease in activity. Preferably, additions and deletions if present are located at the 5' or 3' end rather than being internal.

 A "substantial decrease in activity" occurs when the observed activity of γ -secretase is decreased 10 fold or more compared to activity observed using a
25 SEQ. ID. NO. 9 substrate incubated with cell membranes or detergent-solubilized γ -secretase in the presence of 0.25% CHAPSO in buffer B (50 mM PIPES, pH 7.0, 5 mM MgCl_2 , 5 mM CaCl_2 , 150 mM KCl) at 37°C (described in Example 4, *infra.*). In different embodiments there is less than a 5 fold or 2 fold decrease in activity.

 Substitutions in the substrate not causing a substantial decrease in
30 activity can be initially designed taking into account differences in naturally occurring amino acid R groups. An R group affects different properties of the amino acid such as physical size, charge and hydrophobicity. Amino acids can be divided into different groups as follows: neutral and hydrophobic (alanine, valine, leucine, isoleucine, proline, tryptophan, phenylalanine, and methionine); neutral and polar

(glycine, serine, threonine, tyrosine, cysteine, asparagine, and glutamine); basic (lysine, arginine, and histidine); and acidic (aspartic acid and glutamic acid).

Generally, in substituting different amino acids it is preferable to exchange amino acids having similar properties. Substituting different amino acids within a particular group, such as substituting valine for leucine, arginine for lysine, and asparagine for glutamine are good candidates for not causing a change in polypeptide functioning.

Changes outside of different amino acids groups can also be made. Preferably, such changes are made taking into account the position of the amino acid to be substituted in the polypeptide. For example, arginine can substitute more freely for nonpolar amino acids in the interior of a polypeptide than glutamate because of its long aliphatic side chain. (*See, Ausubel, Current Protocols in Molecular Biology, John Wiley, 1987-1998, Supplement 33 Appendix 1C.*)

SEQ. ID. NO. 1 provides an example of a β -CTF domain. SEQ. ID. NO. 1 is a naturally occurring sequence corresponding to the β -CTF portion of APP (amino acids 596-695) along with an N-terminus methionine. The N-terminus methionine facilitates recombinant production of the substrate. SEQ. ID. NO. 1 is as follows:

SEQ. ID. NO. 1: MDAEFRHDSGYEVHHQKLVFFAEDVGSNKGAIIGLMVGGGV
VIATVIVITLVMLKKKQYTSIHGVEVDAAVTPEERHLSKMQQNGYENP
TYKFFEQMQN.

Derivatives of the β -CTF portion of APP provided in SEQ. ID. NO. 1 that are able to be cleaved *in vivo* by γ -secretase are well known in the art. (See, for example, Lichtenthaler *et al.*, 1997. *Biochemistry* 36, 15396-15403; and Selkoe, 1999. *Nature* 399:A23-A31, which is not admitted to be prior art to the claimed invention.) Such derivatives can themselves provide a β -CTF domain or can serve as a starting point for creating additional derivatives.

Examples of naturally occurring derivatives of SEQ. ID. NO. 1 are provided by SEQ. ID. NOs. 2-7. SEQ. ID. NOs. 2-7 correspond to the β -CTF portion of APP (amino acids 596-695) and also contain an N-terminus methionine. SEQ. ID. NOs. 2-7, where differences between these sequences and SEQ. ID. NO. 1 are highlighted, are provided as follows:

SEQ. ID. NO. 2: MDAEFRHDSGYEVHHQKLVFFAEDVGSNKGAIIGLMVGGV
VIATVVITL VMLKKKQYTSIHG VVEVDAAVTPEERHLSKMQQNGYENP
TYKFFEQMQN;

5 SEQ. ID. NO. 3: MDAEFRHDSGYEVHHQKLVFFAEDVGSNKGAIIGLMVGGV
VIATVIITL VMLKKKQYTSIHG VVEVDAAVTPEERHLSKMQQNGYENP
TYKFFEQMQN;

SEQ. ID. NO. 4: MDAEFRHDSGYEVHHQKLVFFAEDVGSNKGAIIGLMVGGV
10 VIATVIGITL VMLKKKQYTSIHG VVEVDAAVTPEERHLSKMQQNGYENP
TYKFFEQMQN;

SEQ. ID. NO. 5: MDAEFRHDSGYEVHHQKLVFFAEDVGSNKGAIIGLMVGGV
VIATVIITL VMLKKKQYTSIHG VVEVDAAVTPEERHLSKMQQNGYENP
15 TYKFFEQMQN;

SEQ. ID. NO. 6: MDAEFRHDSGYEVHHQKLVFFGEDVGSNKGAIIGLMVGGV
VIATVIVITL VMLKKKQYTSIHG VVEVDAAVTPEERHLSKMQQNGYENP
20 TYKFFEQMQN;

SEQ. ID. NO. 7: MDAEFRHDSGYEVHHQKLVFFAQDVGSNKGAIIGLMVGGV
VIATVIVITL VMLKKKQYTSIHG VVEVDAAVTPEERHLSKMQQNGYENP
TYKFFEQMQN.

25 In an embodiment of the present invention, the β -CTF domain
sequence comprises, consists essentially of, or consists of, a polypeptide substantially
similar to SEQ. ID. NO. 1. Preferably, the β -CTF domain sequence comprises,
consists essentially of, or consists of, a sequence selected from the group consisting of
SEQ. ID. NO. 1, SEQ. ID. NO. 2, SEQ. ID. NO. 3, SEQ. ID. NO. 4, SEQ. ID. NO. 5,
30 SEQ. ID. NO. 6, and SEQ. ID. NO. 7.

“Substantially similar” indicates a sequence similarity of at least about
80% to a reference sequence. In different embodiments the sequence similarity is at
least about 90%, at least about 95% or 100%. Sequence similarity can be determined
using techniques well known in the art, such as those described by Altschul *et al.*,
35 1997. *Nucleic Acids Res.* 25, 3389-3402, hereby incorporated by reference herein. In

one embodiment sequence similarity is determined using tBLASTn search program with the following parameters: MATRIX:BLOSUM62, PER RESIDUE GAP COST: 11, and Lambda ratio: 1.

“Consists essentially” indicates that the reference sequence can be modified by N-terminal and/or C-terminal additions or deletions that do not cause a substantial decrease in the ability of the γ -secretase substrate to be cleaved compared to the reference sequence. Preferably, additions or deletions if present are less than 5 amino acids on either end. An example of a deletion is the removal of the N-terminal methionine.

A substantial decrease in the ability of the γ -secretase substrate to be cleaved is a decrease of 10 fold or more compared to activity observed using a reference substrate incubated with cell membranes or detergent-solubilized γ -secretase in the presence of 0.25% CHAPSO in buffer B (50 mM PIPES, pH 7.0, 5 mM $MgCl_2$, 5 mM $CaCl_2$, 150 mM KCl) at 37°C (described in Example 4, *infra.*). In different embodiments there is less than a 5 fold or 2 fold decrease in activity.

The second component of the γ -secretase substrate, the hydrophilic polypeptide moiety, is preferably chosen to increase the solubility of the γ -secretase substrate in a zwitterionic detergent. Hydrophilic moieties can be obtained taking into account the known charges and polarity of different amino acid R groups. Preferably, the presence of the hydrophilic moiety does not result in a substrate having a substantial decrease in activity.

Different embodiments concerning the overall length and charge of the hydrophilic moiety are provided as follows: in different embodiments concerning the length, the length is about 5 to about 20 amino acids, about 8 to about 12 amino acids, or about 8 amino acids; in different embodiments concerning the overall charge, the charge is greater than ± 2 , ± 3 , or ± 4 . With respect to a negative charge, a greater charge indicates a higher negative charge value.

Preferably, the hydrophilic moiety comprises, consists essentially of, or consists of, a polypeptide substantially identical to SEQ. ID. NO. 8: DYKDDDDK. Substantially identical to SEQ. ID. NO. 8 indicates that within a corresponding 8 amino acid stretch (no gaps) there is a two, one, or zero amino acid difference. Preferably, the hydrophilic moiety consists of the amino acid sequence of SEQ. ID. NO. 8.

In an embodiment of the present invention concerning the overall structure of the γ -secretase substrate, the γ -secretase substrate comprises, consists

essentially of, or consists of, a sequence substantially similar to SEQ. ID. NO. 9. SEQ. ID. NO. 9 corresponds to SEQ. ID. NO. 1 along with a carboxyl terminal SEQ. ID. NO. 8 sequence. Preferably, the γ -secretase substrate comprises, consists essentially of, or consists of, a sequence selected from the group consisting of: SEQ. ID. NO. 9, SEQ. ID. NO. 10, SEQ. ID. NO. 11, SEQ. ID. NO. 12, SEQ. ID. NO. 13, SEQ. ID. NO. 14, and SEQ. ID. NO. 15.

SEQ. ID. NOs. 9-15 are provided as follows (differences between SEQ. ID. NO. 9 and SEQ. ID. NOs. 10-15 are noted in bold and underlined):

10 SEQ. ID. NO. 9: MDAEFRHDSGYEVHHQKLVFFAEDVGSNKGAIIGLMVGGV
VIATVIVITLVMLKKKQYTSIHGVEVDAAVTPEERHLSKMQQNGYENP
TYKFFEQMNDYKDDDDK;

SEQ. ID. NO. 10: MDAEFRHDSGYEVHHQKLVFFAEDVGSNKG
15 AIIGLMVGGVVIATVVITLVMLKKKQYTSIHGVEVDAAVTPEERHLS
KMQQNGYENPTYKFFEQMNDYKDDDDK;

SEQ. ID. NO. 11: MDAEFRHDSGYEVHHQKLVFFAEDVGSNKG
AIIGLMVGGVVIATVIITLVMLKKKQYTSIHGVEVDAAVTPEERHLS
20 KMQQNGYENPTYKFFEQMNDYKDDDDK;

SEQ. ID. NO. 12: MDAEFRHDSGYEVHHQKLVFFAEDVGSNKG
AIIGLMVGGVVIATVIGITLVMLKKKQYTSIHGVEVDAAVTPEERHLS
KMQQNGYENPTYKFFEQMNDYKDDDDK;

25 SEQ. ID. NO. 13: MDAEFRHDSGYEVHHQKLVFFAEDVGSNKG
AIIGLMVGGVVIATVIFITLVMLKKKQYTSIHGVEVDAAVTPEERHLS
KMQQNGYENPTYKFFEQMNDYKDDDDK;

30 SEQ. ID. NO. 14: MDAEFRHDSGYEVHHQKLVFFGEDVGSNKG
AIIGLMVGGVVIATVIVITLVMLKKKQYTSIHGVEVDAAVTPEERHLS
KMQQNGYENPTYKFFEQMNDYKDDDDK;

SEQ. ID. NO. 15: MDAEFRHDSGYEVHHQKLVFFAQDVGSNKG
 AIIGLMVGGVVIA TVIVITLVMILKKKQYTSIHG VVEVDAAVTPEERHLS
 KMQQNGYENPTYKFFEQMQNDYKDDDDK.

5 Based on the disclosure provided herein γ -secretase substrates can be produced using standard biochemical synthesis and recombinant nucleic acid techniques. Techniques for chemical synthesis of polypeptides are well known in the art. (See, for example, Vincent, in *Peptide and Protein Drug Delivery*, New York, N.Y., Dekker, 1990.)

10 Recombinant synthesis techniques for polypeptides are also well known in the art. Such techniques employ a nucleic acid template for polypeptide synthesis. Starting with a particular amino acid sequence and the known degeneracy of the genetic code, a large number of different encoding nucleic acid sequences can be obtained. The degeneracy of the genetic code arises because almost all amino
 15 acids are encoded by different combinations of nucleotide triplets or "codons". The translation of a particular codon into a particular amino acid is well known in the art (see, e.g., Lewin *GENES IV*, p. 119, Oxford University Press, 1990).

Amino acids are encoded for by codons as follows:

A=Ala=Alanine: codons GCA, GCC, GCG, GCU
 20 C=Cys=Cysteine: codons UGC, UGU
 D=Asp=Aspartic acid: codons GAC, GAU
 E=Glu=Glutamic acid: codons GAA, GAG
 F=Phe=Phenylalanine: codons UUC, UUU
 G=Gly=Glycine: codons GGA, GGC, GGG, GGU
 25 H=His=Histidine: codons CAC, CAU
 I=Ile=Isoleucine: codons AUA, AUC, AUU
 K=Lys=Lysine: codons AAA, AAG
 L=Leu=Leucine: codons UUA, UUG, CUA, CUC, CUG, CUU
 M=Met=Methionine: codon AUG
 30 N=Asn=Asparagine: codons AAC, AAU
 P=Pro=Proline: codons CCA, CCC, CCG, CCU
 Q=Gln=Glutamine: codons CAA, CAG
 R=Arg=Arginine: codons AGA, AGG, CGA, CGC, CGG, CGU
 S=Ser=Serine: codons AGC, AGU, UCA, UCC, UCG, UCU

T=Thr=Threonine: codons ACA, ACC, ACG, ACU

V=Val=Valine: codons GUA, GUC, GUG, GUU

W=Trp=Tryptophan: codon UGG

Y=Tyr=Tyrosine: codons UAC, UAU

5 Recombinant synthesis of polypeptides is achieved in a host cell using
an expression vector. An expression vector contains recombinant nucleic acid
encoding for a desired polypeptide along with regulatory elements for proper
transcription and processing. The regulatory elements that may be present include
those naturally associated with the recombinant nucleic acid and exogenous regulatory
10 elements not naturally associated with the recombinant nucleic acid. Exogenous
regulatory elements such as an exogenous promoter can be useful for expressing
recombinant nucleic acid in a particular host.

 Generally, the regulatory elements that are present in an expression
vector include a transcriptional promoter, a ribosome binding site, a terminator, and
15 an optionally present operator. A preferred element is a polyadenylation signal
providing for processing in eukaryotic cells. Other preferred elements include an
origin of replication for autonomous replication in a host cell, a selectable marker, a
limited number of useful restriction enzyme sites, and a potential for high copy
number. Examples of expression vectors are cloning vectors, modified cloning
20 vectors, specifically designed plasmids and viruses.

 Nucleic acid encoding for a polypeptide can be expressed in a cell
without the use of an expression vector employing, for example, synthetic mRNA or
native mRNA. Additionally, mRNA can be translated in various cell-free systems
such as wheat germ extracts and reticulocyte extracts, as well as in cell based systems,
25 such as frog oocytes. Introduction of mRNA into cell based systems can be achieved,
for example, by microinjection.

 Techniques for introducing nucleic acid into an appropriate
environment for expression, for expressing the nucleic acid to produce protein, and
for isolating expressed proteins are well known in the art. Examples of such
30 techniques are provided in references such as Ausubel, *Current Protocols in
Molecular Biology*, John Wiley, 1987-1998, and Sambrook *et al.*, in *Molecular
Cloning, A Laboratory Manual*, 2nd Edition, Cold Spring Harbor Laboratory Press,
1989.

γ -Secretase Assay

The γ -secretase substrate can be employed in assays measuring membrane-bound or detergent-solubilized γ -secretase. Production of cleavage products can be detected by A β peptide or hydrophilic moiety product formation.

5 Solubilized γ -secretase can be obtained from cells producing γ -secretase. Recovery of soluble γ -secretase activity is achieved using a zwitterionic detergent during membrane extraction. Preferably, the amount of zwitterionic detergent is about 1% to about 2%. Examples of cells producing γ -secretase include HeLa S3, human embryonic kidney (HEK293) cells and Chinese hamster ovary
10 (CHO) cells. Examples of zwitterionic detergents include CHAPSO and CHAPS.

Assay conditions employing membrane-bound or detergent-solubilized γ -secretase allow for detectable γ -secretase activity. Such conditions include an effective amount of a zwitterionic detergent, a buffer, and an appropriate temperature.

An effective amount of a particular zwitterionic detergent results in
15 detectable cleavage. Suitable detergents and amounts can be determined by evaluating the effect of a particular detergent on γ -secretase activity. Preferred zwitterionic detergents present during the assay are CHAPS and CHAPSO. A preferred percentage of such detergents is about 0.1% to about 0.5%.

An example of a reaction condition allowing for γ -secretase activity is
20 provided as follows: 1.7 μ M substrate incubated with cell membranes or detergent solubilized γ -secretase in the presence of 0.25% CHAPSO in buffer B (50 mM PIPES, pH 7.0, 5 mM MgCl₂, 5 mM CaCl₂, 150 mM KCl) at 37°C (described in Example 4, *infra*). Such conditions can be used as a standard to determine effects of different components. Based on the present disclosure such reaction conditions can
25 be altered to provide a wide range of additional reaction conditions allowing for γ -secretase activity. Preferably, changes to the reaction conditions do not result in a substantial decrease in activity.

γ -Secretase activity can be stopped using techniques well known in the art for stopping enzymatic reactions. Preferably, γ -secretase activity is stopped using
30 reagents compatible with subsequent analysis.

Cleavage of γ -secretase substrates can be measured by detecting formation of an A β type product or a product containing the hydrophilic moiety. The presence of either of these products can be measured using techniques such as those employing antibodies and radioactive, electrochemiluminescent or fluorescent labels.

If needed or desirable, a purification step enriching the different products may be employed. Examples of purification steps include the use of antibodies, separation gels, and columns.

Preferably, cleavage of γ -secretase is assayed for by detecting the presence of A β -40 or A β -42. Figure 1 illustrates a preferred method for product detection employing electrochemiluminescence with a capture antibody and an antibody specific for either A β -40 or A β -42. The capture antibody is used to enrich the products and hence, produce a higher signal.

10

EXAMPLES

Examples are provided below to further illustrate different features and advantages of the present invention. The examples also illustrate useful methodology for practicing the invention. These examples do not limit the claimed invention.

15 Example 1: Recombinant Production of the γ -Secretase Substrate

A DNA fragment encoding amino acids 596-695 of the 695 amino acid isoform of APP (APP695) and SEQ. ID. NO. 8 at the C-terminus was generated by PCR amplification of APP695 cDNA using appropriate primers. The employed primers had the following sequences: SEQ. ID. NO. 16: ggaattccatATGGATGCAG
20 AATTCCGACATG; and SEQ. ID. NO. 17: cgcgatccCTAttatcgtcatcgtctttgtatcGTTCTGCATCTGCTCAAAGAACTTG.

The Met that serves as the translation start site is residue 596 of APP695 (the P1 residue with respect to the β -secretase cleavage site). This DNA fragment was inserted into the procaryotic expression vector pET2-21b (Novagen,
25 Madison WI). The recombinant protein of SEQ. ID. NO. 9 was overproduced in *E. coli* [strain BL21(DE3)] and purified by Mono-Q column chromatography (Pharmacia Biotech).

SEQ. ID. NO. 18 provides a nucleic acid sequence encoding for the recombinant protein of SEQ. ID. NO. 9 along with a stop codon.

30

SEQ. ID. NO. 18: ATGGATGCAGAATTCCGACATGACTCAGGATATGAAGT
TCATCATCAAAAATTGGTGTCTTTGCAGAAGATGTGGGTTCAAACAAAG
GTGCAATCATTGGACTCATGGTGGGCGGTGTTGTCATAGCGACAGTGATC
GTCATCACCTTGGTGATGCTGAAGAAGAAACAGTACACATCCATTCATCA
35 TGGTGTGGTGGAGGTTGACGCCGCTGTCACCCCAGAGGAGCGCCACCTGT

CCAAGATGCAGCAGAACGGCTACGAAAATCCAACCTACAAGTTCTTTGAG
CAGATGCAGAACgactacaagacgatgacgataaaTAG

Example 2: A β Peptide Detection

5 The A β peptides were detected using a sandwich assay employing an antibody to capture the peptide and an antibody to detect the presence of the peptide. Detection was achieved by using ECL (Yang *et al.*, 1994. *Bio/Technology* 12, 193-194; Khorkova *et al.*, 1998. *Journal of Neuroscience Methods* 82, 159-166), and an Origen 1.5 Analyzer (Igen Inc., Gaithersburg, MD).

10 Capture was performed using the 4G8 murine monoclonal antibody (Senetek PLC, Maryland Heights, MO). The 4G8 murine monoclonal antibody binds an epitope in the A β peptide (within amino acids 18-21) that is immediately distal to the α -secretase cleavage site. The 4G8 monoclonal antibody was biotinylated with Biotin-LC-Sulfo-NHS-Ester (Igen Inc.).

15 Detection was achieved using the G2-10 murine monoclonal antibody and the FCA3542 rabbit antibody. The G2-10 murine monoclonal antibody (provided by K. Beyreuther, University of Heidelberg, Germany) binds the C-terminus that is exposed after γ -secretase-mediated cleavage to generate amino acid 40 of the A β 40 peptide. (Ida *et al.*, 1996. *J. Biol. Chem.* 271, 22908-22914). The FCA3542 rabbit
20 antibody (provided by F. Checler, IPMC du CNRS, Valbonne, France) binds the C-terminus that is exposed after γ -secretase-mediated cleavage to generate amino acid 42 of the A β 42 peptide. (Barelli *et al.*, 1997. *Molecular Medicine* 3, 695-707.)

 The G2-10 and FCA3542 antibodies were ruthenylated with TAG-NHS Ester (Igen Inc.). A β (x-40) was detected with biotinylated 4G8 and ruthenylated
25 G2-10. A β (x-42) was detected with biotinylated 4G8 and ruthenylated FCA3542.

Example 3: Membrane Preparation and Detergent Solubilization

 HeLa S3 cells from American Type Culture Collection (Rockville, MD) were grown in bioreactors (Analytical Biological Services; Wilmington, DE) in
30 90% DMEM, 10% fetal bovine serum, 2 mM glutamine and 100 μ g/ml each of penicillin and streptomycin. Frozen HeLa S3 cells were resuspended in buffer A (50 mM MES, pH 6.0, 5 mM MgCl₂, 5 mM CaCl₂, 150 mM KCl) containing "complete" protease inhibitor cocktail (Boehringer Mannheim, Indianapolis, IN). The cells were broken by single-pass through a French Press (Spectronic Instruments, Rochester,
35 NY). Cell debris and nuclei were removed by centrifugation at 800 x g for 10

minutes. The supernatant solutions were centrifuged at 100,000 x g for 60 minutes. The ensuing pellets were resuspended in buffer A and the centrifugation was repeated. The final membrane pellets were resuspended in buffer A to yield a protein concentration of approximately 12 mg/ml. All procedures were performed at 4°C.

5 The membranes were stored at -70°C.

HeLa cell membranes were treated with varying amounts of CHAPSO (up to 2.0%) followed by centrifugation. The supernatant solutions (solubilized fractions) and the pellets (membrane fractions) were then assayed for γ -secretase activity with the SEQ. ID. NO. 9 substrate.

10 More γ -secretase activity is recovered in the solubilized fraction, relative to the detergent-extracted membrane fraction, as the CHAPSO concentration is raised stepwise to 1.0% (Table I). The amounts of γ -secretase activity that are solubilized by 1.0% and 2.0% CHAPSO are comparable. There are corresponding decreases in pellet-associated γ -secretase activity as a result of the CHAPSO
15 extraction.

TABLE I

Extraction of γ -secretase activity with CHAPSO detergent					
	CHAPSO concentration				
γ -secretase preparation	0%	0.25%	0.50%	1.00%	2.0%
Solubilized	< 1	3	35	49	50
Membranes	> 99	97	65	51	50

20 Values show the % of total γ -secretase activity in each fraction (Solubilized versus Membranes) at each CHAPSO concentration.

Standard detergent solubilization of HeLa cell membranes (protein concentration, 2.5 mg/ml in buffer A) involved treatment with 1% CHAPSO for 60 minutes at 4°C and centrifugation at 100,000 x g for 60 minutes. The ensuing
25 supernatant solution provides "solubilized γ -secretase". Approximately 50% of the γ -secretase activity in the HeLa cell membranes is solubilized by this CHAPSO extraction protocol. The total recovery of γ -secretase activity in the "solubilized γ -secretase" and residual pellet is approximately 50% greater than that observed with the intact membranes (data not shown).

Example 4: *In Vitro* γ -Secretase Assay


In vitro assays measuring γ -secretase activity were performed using cell membranes or as "solubilized γ -secretase". In one reaction, SEQ. ID. NO. 9 substrate (1.7 μ M) was incubated with cell membranes (0.5 mg/ml) in presence of detergent in buffer B (50 mM PIPES, pH 7.0, 5 mM $MgCl_2$, 5 mM $CaCl_2$, 150 mM KCl) at 37°C. In another reaction, supernatant solution from CHAPSO-extracted HeLa cell membranes ("solubilized γ -secretase") was incubated with SEQ. ID. NO. 9 substrate at 37°C in the presence of detergent in buffer B. Generally, 0.25% CHAPSO was provided as the detergent. The reactions were stopped by adding RIPA (150 mM NaCl, 1.0% NP-40, 0.5% DOC, 0.1% SDS, 50 mM Tris HCl, pH 8.0).

The samples were centrifuged and the supernatant solutions were assayed for the A β peptides by ECL. The A β 40- and A β 42-related products from γ -secretase-mediated processing of SEQ. ID. NO. 9 substrate possess a Met at the N-terminus and are thus defined as M-A β 40 and M-A β 42, respectively.

Example 5: Inhibition Studies

Inhibition studies was performed to demonstrate that the γ -secretase activity in "solubilized γ -secretase" is catalyzed by the *bona fide* APP processing enzyme in cells and is not simply due to a spurious proteolytic activity. The studies examined the effects of L-685,458 on cleavage at the γ -secretase scissile bond of the substrates in both the cellular and *in vitro* assays.

L-685,458 is a putative γ -secretase inhibitor having the following structure:



The effect of a γ -secretase inhibitor on γ -secretase activity was measured using Chinese hamster ovary fibroblasts that stably express APP695 (CHO/APP695, provided by Dr. S. Sisodia (University of Chicago, Chicago, IL)). CHO/APP695 were grown in 90% DMEM, 10% fetal bovine serum, 2 mM
5 glutamine, 100 μ g/ml each of penicillin and streptomycin, and 0.2 mg/ml G418. CHO/APP695 cells were seeded in 96-well dishes at 2×10^4 cells/well. A β -peptide formation was detected by either ECL or using radiolabeling.

For ECL detection, the media was replenished the next day with or without L-685,458. The A β (x-40) and A β (x-42) levels in the 24 hour conditioned
10 media (CM) were measured by ECL.

For the radiolabeling experiments, CHO/APP695 cells (in 100 mm dishes) were grown to 70% confluency in complete media. Afterwards, these cells were cultured \pm 1 μ M L-685,458 for 24 hours, switched to Met-free medium (+/- 1 μ M L-685,458) for 20 minutes, pulsed with 1 mCi/ml of S³⁵-Met (Amersham Life
15 Sciences, Inc, Arlington Heights, IL) in Met-free medium (+/- 1 μ M L-685,458) for 2 hours, and subsequently chased in complete medium (+/- 1 μ M L-685,458) for 45 minutes. The cells were washed with Hanks balanced salt solution and lysed with 1 ml of RIPA. The insoluble residue was removed by centrifugation. The 4G8 antibody (final concentration, 2 μ g/ml) was added to the supernatant fractions. The
20 samples were gently rotated overnight at 4°C. Protein G-agarose beads (Pharmacia Biotech, Piscataway, NJ) were added the next day, the samples were rotated for an additional 2 hours and then centrifuged. The protein G-agarose beads from the 4G8 immunoprecipitation step were washed 4 times with RIPA. An equal volume of SDS sample buffer (Novex, San Diego, CA) was added and the samples were boiled for 5
25 minutes and fractionated by SDS-polyacrylamide gel electrophoresis (SDS-PAGE) using 16% polyacrylamide-Tricine gels (Novex). ¹⁴C-labeled protein markers (Amersham Life Sciences) were co-electrophoresed. The gel was dried and exposed to X-Omatic film (Kodak, Rochester, NY) for 24-72 hours.

Treatment of CHO/APP695 cells with L-685,458 results in the
30 intracellular accumulation of APP immunoreactive fragments that co-migrate with α -CTF and β -CTF (data not shown) – a result that is consistent with γ -secretase inhibition. Moreover, L-685,458 blocked A β 40 and A β 42 secretion from CHO/APP695 cells in a dose-dependent manner with IC₅₀ values for suppression of A β 40 and A β 42 secretion of 130 and 200 nM, respectively.

Similarly, L-685,458 inhibits "solubilized γ -secretase" mediated processing of SEQ. ID. NO. 9 substrate that results in the generation of the A β 40- and A β 42-related products. The IC₅₀ values for inhibition of the A β 40 and A β 42 cleavage events in the *in vitro* assay are both approximately 1 nM. All of the apparent
5 "solubilized γ -secretase" activity is inhibited by L-685,458.

Example 6: Characterization of Product Formation

Incubation of HeLa cell membranes or "solubilized γ -secretase" with SEQ. ID. NO. 9 substrate generates M-A β 42 and M-A β 40. The A β 42/A β 40 cleavage
10 ratios, approximately 0.1, with both intact membranes and "solubilized γ -secretase" are similar to the corresponding ratio that has been reported for A β peptides secreted into the CM of cultured cells that are overexpressing APP (Asami-Odaka *et al.*, 1995. *Biochemistry* 34, 10272-10278).

The apparent K_m value of "solubilized γ -secretase" for SEQ. ID. NO. 9
15 substrate (assaying for A β 40 cleavage) is approximately 1 μ M (Fig. 2A). Under the experimental conditions employed, the time dependence of product formation is linear over a 3 hour interval (Fig 2B). The production of the M-A β 40 and M-A β 42 are both blocked by pepstatin, a classical inhibitor of aspartyl class proteases (Figure 2D). The IC₅₀ values of pepstatin for inhibiting the generation of the A β 40 and A β 42 termini
20 are 4.0 and 5.9 μ M, respectively.

Example 7: pH Dependency

The pH dependence of *in vitro* γ -secretase activity was determined using pH-adjusted 50 mM MES and 50 mM PIPES for the pH 5.0-6.5 and pH 6.5-9.0
25 ranges, respectively. The pH dependence of "solubilized γ -secretase" activity showed a pH optimum of 7.0 (Figure 2C).

Example 8: Detergent Effect

SEQ. ID. NO. 9 substrate (1.7 μ M) was incubated with cell membranes
30 (0.5 mg/ml) in presence of CHAPSO, CHAPS or Triton X-100 (0, 0.125, 0.25, 0.5, or 1%) in buffer B at 37°C. The results are shown in Table II.

TABLE II

M-A β 40 production (ECL signal X 10 ⁻⁶)			
[Detergent]	CHAPSO	CHAPS	Triton X-100
(%)			
0	0.03	0.03	0.03
0.125	2.2	0.03	0.02
0.25	8.74	3.21	0.02
0.5	1.22	0.27	0.02
0.75	0.07	0.04	0.02
1	0.03	0.03	0.02

Simple addition of SEQ. ID. NO. 9 substrate to membranes prepared from HeLa cells does not lead to substrate cleavage and generation of M-A β 40. Inclusion of CHAPSO or CHAPS during the incubation of HeLa cell membranes and SEQ. ID. NO. 9 substrate promotes cleavage at the γ -secretase scissile bond. Triton X-100 fails to potentiate *in vitro* γ -secretase activity. Optimal activity is observed in the presence of 0.25% CHAPSO. Higher concentrations of CHAPSO lead to a progressive decline in γ -secretase activity. Membranes prepared from human embryonic kidney (HEK293) cells or Chinese hamster ovary (CHO) cells also process SEQ. ID. NO. 9 substrate in the presence of 0.25% CHAPSO to generate M-A β 40 (data not shown).

Other embodiments are within the following claims. While several embodiments have been shown and described, various modifications may be made without departing from the spirit and scope of the present invention.

WHAT IS CLAIMED IS:

1. A γ -secretase substrate consisting of:
 - a) a β -CTF domain; and
 - b) a hydrophilic polypeptide moiety covalently joined to the carboxyl terminus of said β -CTF domain.
2. The substrate of claim 1, wherein said β -CTF domain is substantially similar to SEQ. ID. NO. 1.
3. The substrate of claim 2, wherein said β -CTF domain consists essentially of a sequence selected from the group consisting of: SEQ. ID. NO. 1, SEQ. ID. NO. 2, SEQ. ID. NO. 3, SEQ. ID. NO. 4, SEQ. ID. NO. 5, SEQ. ID. NO. 6, and SEQ. ID. NO. 7.
4. The substrate of claim 3, wherein said hydrophilic polypeptide moiety is about 5 to about 15 amino acids in length and contains a net charge that is greater than ± 2 (absolute value).
5. The substrate of claim 4, where said hydrophilic moiety is about 8 amino acids in length and contains a net charge that is greater than -2 (absolute value).
6. The substrate of claim 5, wherein said β -CTF domain consists of a sequence selected from the group consisting of: SEQ. ID. NO. 1, SEQ. ID. NO. 2, SEQ. ID. NO. 3, SEQ. ID. NO. 4, SEQ. ID. NO. 5, SEQ. ID. NO. 6, and SEQ. ID. NO. 7.
7. The substrate of claim 1, wherein said substrate is substantially similar to SEQ. ID. NO. 9.
8. The substrate of claim 7, wherein said substrate consists of a sequence selected from the group consisting of: SEQ. ID. NO. 9, SEQ. ID. NO. 10, SEQ. ID. NO. 11, SEQ. ID. NO. 12, SEQ. ID. NO. 13, SEQ. ID. NO. 14, and SEQ. ID. NO. 15.

9. The substrate of claim 8, wherein said substrate consists of
SEQ. ID. NO. 9.
- 5 10. A nucleic acid comprising a nucleotide base sequence encoding
for the substrate of claim 1.
- 10 11. The nucleic acid of claim 10, wherein said nucleic acid is an
expression vector.
12. A recombinant cell comprising the nucleic acid of claim 10.
13. A method for assaying γ -secretase activity comprising the step
of measuring cleavage of the substrate of any one of claims 1-9 by γ -secretase in the
15 presence of an effective amount of a zwitterionic detergent.
14. The method of claim 13, wherein said zwitterionic detergent is
either CHAPS or CHAPSO.
- 20 15. The method of claim 14, wherein said effective amount is about
0.25%.
16. The method of claim 15, wherein said measuring comprises the
use of an antibody that binds to the carboxyl terminus of the A β peptide-related
25 product produced by said cleavage.
17. The method of claim 16, wherein said method is performed in
the presence of one or more compounds that inhibit γ -secretase activity.
- 30 18. A method for measuring the ability of a compound to affect γ -
secretase activity comprising the steps of:
- a) combining together the substrate of any one of claims
1-9, said compound, and a preparation comprising γ -secretase activity, under reaction
conditions allowing for γ -secretase activity, wherein said reaction conditions comprise
35 an effective amount of a zwitterionic detergent; and

b) measuring γ -secretase activity.

19. The method of claim 18, wherein said zwitterionic detergent is either CHAPS or CHAPSO.

5

1/5




Fig. 1

2/5




Fig. 2A

3/5




Fig. 2B

4/5




Fig. 2C

5/5




Fig. 2D

SEQUENCE LISTING

<110> Merck & Co., Inc.

<120> GAMMA SECRETASE SUBSTRATES AND IN VITRO ASSAYS

<130> 20507 PCT

<150> 60/201,053

<151> 2000-05-01

<160> 18

<170> FastSEQ for Windows Version 4.0

<210> 1

<211> 100

<212> PRT

<213> Artificial Sequence

<220>

<223> Beta-CTF domain

<400> 1

Met	Asp	Ala	Glu	Phe	Arg	His	Asp	Ser	Gly	Tyr	Glu	Val	His	His	Gln
1				5					10					15	
Lys	Leu	Val	Phe	Phe	Ala	Glu	Asp	Val	Gly	Ser	Asn	Lys	Gly	Ala	Ile
			20					25					30		
Ile	Gly	Leu	Met	Val	Gly	Gly	Val	Val	Ile	Ala	Thr	Val	Ile	Val	Ile
		35					40					45			
Thr	Leu	Val	Met	Leu	Lys	Lys	Lys	Gln	Tyr	Thr	Ser	Ile	His	His	Gly
	50					55					60				
Val	Val	Glu	Val	Asp	Ala	Ala	Val	Thr	Pro	Glu	Glu	Arg	His	Leu	Ser
65				70						75				80	
Lys	Met	Gln	Gln	Asn	Gly	Tyr	Glu	Asn	Pro	Thr	Tyr	Lys	Phe	Phe	Glu
				85				90						95	
Gln	Met	Gln	Asn												
			100												

<210> 2

<211> 100

<212> PRT

<213> Artificial Sequence

<220>

<223> Beta-CTF domain

<400> 2

Met	Asp	Ala	Glu	Phe	Arg	His	Asp	Ser	Gly	Tyr	Glu	Val	His	His	Gln
1				5					10					15	
Lys	Leu	Val	Phe	Phe	Ala	Glu	Asp	Val	Gly	Ser	Asn	Lys	Gly	Ala	Ile
			20					25					30		
Ile	Gly	Leu	Met	Val	Gly	Gly	Val	Val	Ile	Ala	Thr	Val	Val	Val	Ile
		35					40					45			
Thr	Leu	Val	Met	Leu	Lys	Lys	Lys	Gln	Tyr	Thr	Ser	Ile	His	His	Gly
	50					55					60				
Val	Val	Glu	Val	Asp	Ala	Ala	Val	Thr	Pro	Glu	Glu	Arg	His	Leu	Ser
65				70						75				80	
Lys	Met	Gln	Gln	Asn	Gly	Tyr	Glu	Asn	Pro	Thr	Tyr	Lys	Phe	Phe	Glu
				85				90						95	

Gln Met Gln Asn
100

<210> 3
<211> 100
<212> PRT
<213> Artificial Sequence

<220>
<223> Beta-CTF domain

<400> 3
Met Asp Ala Glu Phe Arg His Asp Ser Gly Tyr Glu Val His His Gln
1 5 10 15
Lys Leu Val Phe Phe Ala Glu Asp Val Gly Ser Asn Lys Gly Ala Ile
20 25 30
Ile Gly Leu Met Val Gly Gly Val Ile Ala Thr Val Ile Ile Ile
35 40 45
Thr Leu Val Met Leu Lys Lys Lys Gln Tyr Thr Ser Ile His His Gly
50 55 60
Val Val Glu Val Asp Ala Ala Val Thr Pro Glu Glu Arg His Leu Ser
65 70 75 80
Lys Met Gln Gln Asn Gly Tyr Glu Asn Pro Thr Tyr Lys Phe Phe Glu
85 90 95
Gln Met Gln Asn
100

<210> 4
<211> 100
<212> PRT
<213> Artificial Sequence

<220>
<223> Beta-CTF domain

<400> 4
Met Asp Ala Glu Phe Arg His Asp Ser Gly Tyr Glu Val His His Gln
1 5 10 15
Lys Leu Val Phe Phe Ala Glu Asp Val Gly Ser Asn Lys Gly Ala Ile
20 25 30
Ile Gly Leu Met Val Gly Gly Val Val Ile Ala Thr Val Ile Gly Ile
35 40 45
Thr Leu Val Met Leu Lys Lys Lys Gln Tyr Thr Ser Ile His His Gly
50 55 60
Val Val Glu Val Asp Ala Ala Val Thr Pro Glu Glu Arg His Leu Ser
65 70 75 80
Lys Met Gln Gln Asn Gly Tyr Glu Asn Pro Thr Tyr Lys Phe Phe Glu
85 90 95
Gln Met Gln Asn
100

<210> 5
<211> 100
<212> PRT
<213> Artificial Sequence

<220>
<223> Beta-CTF domain

<400> 5
Met Asp Ala Glu Phe Arg His Asp Ser Gly Tyr Glu Val His His Gln
1 5 10 15

```

Lys Leu Val Phe Phe Ala Glu Asp Val Gly Ser Asn Lys Gly Ala Ile
      20      25      30
Ile Gly Leu Met Val Gly Gly Val Val Ile Ala Thr Val Ile Phe Ile
      35      40      45
Thr Leu Val Met Leu Lys Lys Lys Gln Tyr Thr Ser Ile His His Gly
      50      55      60
Val Val Glu Val Asp Ala Ala Val Thr Pro Glu Glu Arg His Leu Ser
      65      70      75      80
Lys Met Gln Gln Asn Gly Tyr Glu Asn Pro Thr Tyr Lys Phe Phe Glu
      85      90      95
Gln Met Gln Asn
      100

```

<210> 6
 <211> 100
 <212> PRT
 <213> Artificial Sequence .

<220>
 <223> Beta-CTF domain

```

<400> 6
Met Asp Ala Glu Phe Arg His Asp Ser Gly Tyr Glu Val His His Gln
  1      5      10      15
Lys Leu Val Phe Phe Gly Glu Asp Val Gly Ser Asn Lys Gly Ala Ile
      20      25      30
Ile Gly Leu Met Val Gly Gly Val Val Ile Ala Thr Val Ile Val Ile
      35      40      45
Thr Leu Val Met Leu Lys Lys Lys Gln Tyr Thr Ser Ile His His Gly
      50      55      60
Val Val Glu Val Asp Ala Ala Val Thr Pro Glu Glu Arg His Leu Ser
      65      70      75      80
Lys Met Gln Gln Asn Gly Tyr Glu Asn Pro Thr Tyr Lys Phe Phe Glu
      85      90      95
Gln Met Gln Asn
      100

```

<210> 7
 <211> 100
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Beta-CTF domain

```

<400> 7
Met Asp Ala Glu Phe Arg His Asp Ser Gly Tyr Glu Val His His Gln
  1      5      10      15
Lys Leu Val Phe Phe Ala Gln Asp Val Gly Ser Asn Lys Gly Ala Ile
      20      25      30
Ile Gly Leu Met Val Gly Gly Val Val Ile Ala Thr Val Ile Val Ile
      35      40      45
Thr Leu Val Met Leu Lys Lys Lys Gln Tyr Thr Ser Ile His His Gly
      50      55      60
Val Val Glu Val Asp Ala Ala Val Thr Pro Glu Glu Arg His Leu Ser
      65      70      75      80
Lys Met Gln Gln Asn Gly Tyr Glu Asn Pro Thr Tyr Lys Phe Phe Glu
      85      90      95
Gln Met Gln Asn
      100

```

<210> 8

<211> 8
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Hydrophilic moiety

<400> 8
 Asp Tyr Lys Asp Asp Asp Asp Lys
 1 5

<210> 9
 <211> 108
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Gamma-secretase substrate

<400> 9
 Met Asp Ala Glu Phe Arg His Asp Ser Gly Tyr Glu Val His His Gln
 1 5 10 15
 Lys Leu Val Phe Phe Ala Glu Asp Val Gly Ser Asn Lys Gly Ala Ile
 20 25 30
 Ile Gly Leu Met Val Gly Gly Val Val Ile Ala Thr Val Ile Val Ile
 35 40 45
 Thr Leu Val Met Leu Lys Lys Lys Gln Tyr Thr Ser Ile His His Gly
 50 55 60
 Val Val Glu Val Asp Ala Ala Val Thr Pro Glu Glu Arg His Leu Ser
 65 70 75 80
 Lys Met Gln Gln Asn Gly Tyr Glu Asn Pro Thr Tyr Lys Phe Phe Glu
 85 90 95
 Gln Met Gln Asn Asp Tyr Lys Asp Asp Asp Asp Lys
 100 105

<210> 10
 <211> 108
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Gamma-secretase substrate

<400> 10
 Met Asp Ala Glu Phe Arg His Asp Ser Gly Tyr Glu Val His His Gln
 1 5 10 15
 Lys Leu Val Phe Phe Ala Glu Asp Val Gly Ser Asn Lys Gly Ala Ile
 20 25 30
 Ile Gly Leu Met Val Gly Gly Val Val Ile Ala Thr Val Val Val Ile
 35 40 45
 Thr Leu Val Met Leu Lys Lys Lys Gln Tyr Thr Ser Ile His His Gly
 50 55 60
 Val Val Glu Val Asp Ala Ala Val Thr Pro Glu Glu Arg His Leu Ser
 65 70 75 80
 Lys Met Gln Gln Asn Gly Tyr Glu Asn Pro Thr Tyr Lys Phe Phe Glu
 85 90 95
 Gln Met Gln Asn Asp Tyr Lys Asp Asp Asp Asp Lys
 100 105

<210> 11
 <211> 108
 <212> PRT

<213> Artificial Sequence

<220>

<223> Gamma-secretase substrate

<400> 11

```

Met Asp Ala Glu Phe Arg His Asp Ser Gly Tyr Glu Val His His Gln
 1           5           10           15
Lys Leu Val Phe Phe Ala Glu Asp Val Gly Ser Asn Lys Gly Ala Ile
           20           25           30
Ile Gly Leu Met Val Gly Gly Val Ile Ala Thr Val Ile Ile Ile
           35           40           45
Thr Leu Val Met Leu Lys Lys Lys Gln Tyr Thr Ser Ile His His Gly
 50           55           60
Val Val Glu Val Asp Ala Ala Val Thr Pro Glu Glu Arg His Leu Ser
65           70           75           80
Lys Met Gln Gln Asn Gly Tyr Glu Asn Pro Thr Tyr Lys Phe Phe Glu
           85           90           95
Gln Met Gln Asn Asp Tyr Lys Asp Asp Asp Asp Lys
           100           105

```

<210> 12

<211> 108

<212> PRT

<213> Artificial Sequence

<220>

<223> Gamma-secretase substrate

<400> 12

```

Met Asp Ala Glu Phe Arg His Asp Ser Gly Tyr Glu Val His His Gln
 1           5           10           15
Lys Leu Val Phe Phe Ala Glu Asp Val Gly Ser Asn Lys Gly Ala Ile
           20           25           30
Ile Gly Leu Met Val Gly Gly Val Ile Ala Thr Val Ile Gly Ile
           35           40           45
Thr Leu Val Met Leu Lys Lys Lys Gln Tyr Thr Ser Ile His His Gly
 50           55           60
Val Val Glu Val Asp Ala Ala Val Thr Pro Glu Glu Arg His Leu Ser
65           70           75           80
Lys Met Gln Gln Asn Gly Tyr Glu Asn Pro Thr Tyr Lys Phe Phe Glu
           85           90           95
Gln Met Gln Asn Asp Tyr Lys Asp Asp Asp Asp Lys
           100           105

```

<210> 13

<211> 108

<212> PRT

<213> Artificial Sequence

<220>

<223> Gamma-secretase substrate

<400> 13

```

Met Asp Ala Glu Phe Arg His Asp Ser Gly Tyr Glu Val His His Gln
 1           5           10           15
Lys Leu Val Phe Phe Ala Glu Asp Val Gly Ser Asn Lys Gly Ala Ile
           20           25           30
Ile Gly Leu Met Val Gly Gly Val Ile Ala Thr Val Ile Phe Ile
           35           40           45
Thr Leu Val Met Leu Lys Lys Lys Gln Tyr Thr Ser Ile His His Gly
 50           55           60

```

Val Val Glu Val Asp Ala Ala Val Thr Pro Glu Glu Arg His Leu Ser
 65 70 75 80
 Lys Met Gln Gln Asn Gly Tyr Glu Asn Pro Thr Tyr Lys Phe Phe Glu
 85 90 95
 Gln Met Gln Asn Asp Tyr Lys Asp Asp Asp Lys
 100 105

<210> 14
 <211> 108
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Gamma-secretase substrate

<400> 14
 Met Asp Ala Glu Phe Arg His Asp Ser Gly Tyr Glu Val His His Gln
 1 5 10 15
 Lys Leu Val Phe Gly Glu Asp Val Gly Ser Asn Lys Gly Ala Ile
 20 25 30
 Ile Gly Leu Met Val Gly Gly Val Val Ile Ala Thr Val Ile Val Ile
 35 40 45
 Thr Leu Val Met Leu Lys Lys Lys Gln Tyr Thr Ser Ile His His Gly
 50 55 60
 Val Val Glu Val Asp Ala Ala Val Thr Pro Glu Glu Arg His Leu Ser
 65 70 75 80
 Lys Met Gln Gln Asn Gly Tyr Glu Asn Pro Thr Tyr Lys Phe Phe Glu
 85 90 95
 Gln Met Gln Asn Asp Tyr Lys Asp Asp Asp Lys
 100 105

<210> 15
 <211> 108
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Gamma-secretase substrate

<400> 15
 Met Asp Ala Glu Phe Arg His Asp Ser Gly Tyr Glu Val His His Gln
 1 5 10 15
 Lys Leu Val Phe Phe Ala Gln Asp Val Gly Ser Asn Lys Gly Ala Ile
 20 25 30
 Ile Gly Leu Met Val Gly Gly Val Val Ile Ala Thr Val Ile Val Ile
 35 40 45
 Thr Leu Val Met Leu Lys Lys Lys Gln Tyr Thr Ser Ile His His Gly
 50 55 60
 Val Val Glu Val Asp Ala Ala Val Thr Pro Glu Glu Arg His Leu Ser
 65 70 75 80
 Lys Met Gln Gln Asn Gly Tyr Glu Asn Pro Thr Tyr Lys Phe Phe Glu
 85 90 95
 Gln Met Gln Asn Asp Tyr Lys Asp Asp Asp Lys
 100 105

<210> 16
 <211> 32
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Primer

<400> 16
 ggaattccat atggatgcag aattccgaca tg 32

<210> 17
 <211> 61
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Primer

<400> 17
 cgcggatccc tatttatcgt catcgtcttt gtagtcgttc tgcattctgct caaagaactt 60
 g 61

<210> 18
 <211> 327
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> DNA Encoding SEQ. ID. NO. 9

<400> 18
 atggatgcag aattccgaca tgactcagga tatgaagttc atcatcaaaa attggtgttc 60
 tttgcagaag atgtgggttc aaacaaaggt gcaatcattg gactcatggt gggcgggtgtt 120
 gtcatagcga cagtgatcgt catcaccttg gtgatgctga agaagaaaca gtacacatcc 180
 attcatcatg gtgtggtgga ggttgacgcc gctgtcacc cagaggagcg ccacctgtcc 240
 aagatgcagc agaacggcta cgaaaatcca acctacaagt tctttgagca gatgcagaac 300
 gactacaaag acgatgacga taaatag 327

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US01/13332**A. CLASSIFICATION OF SUBJECT MATTER**

IPC(7) : Please See Extra Sheet.

US CL : 435/212, 4,7.1; 530/300, 350; 536/23.1

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 435/212, 4,7.1; 530/300, 350; 536/23.1

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

West, CAPLUS, BIOSIS, EMBASE, MEDLINE, CANCERLIT

search terms: yueming li, min xy, qian huag, stephen gardell, gamma secretase

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 5,187,153 A (CORDELL et al.) 16 February 1993, see entire document, especially SEQ ID NO: 10.	1-7
--		---
Y		10-19

☐ Further documents are listed in the continuation of Box C.
 ☐ See patent family annex.

* Special categories of cited documents:	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"A" document defining the general state of the art which is not considered to be of particular relevance	"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"B" earlier document published on or after the international filing date	"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"&" document member of the same patent family
"O" document referring to an oral disclosure, use, exhibition or other means	
"P" document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search

02 JULY 2001

Date of mailing of the international search report

11 OCT 2001

Name and mailing address of the ISA/US
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

PETER TUNG

Telephone No. (703) 308-0196

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US01/13332

A. CLASSIFICATION OF SUBJECT MATTER:

IPC (7):

C12Q 1/00; G01N 33/53; C12N 9/48; A61K 38/00; C07K 14/00; C07H 21/04